New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
09:08 EDTSTEMStemCells expands patent portfolio
StemCells announced that it has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP+ Nestin+ cells, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated GFAP+ Nestin+ cells wherein one or more cells have the capacity to differentiate into neurons and glia as do many neural stem and progenitor cells described by researchers. The invention claimed by the patents resulted from research conducted at NsGene while in pursuit of cell-based treatments for Parkinson's disease. The terms of the patents extend into 2020 and 2021.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
10:35 EDTSTEMStemCells appoints Ian Massey as President and COO effective March 23
Subscribe for More Information
March 16, 2015
16:23 EDTSTEMStemCells reports Q4 EPS (14c), one estimate (4c)
Reports Q4 revenue $883K vs 45K in Q413. "Total revenue from continuing operations during the fourth quarter of 2014 was $883,000, compared to $45,000 in the same period of 2013. Revenue from continuing operations is primarily from royalties and milestone payments received under various licensing agreements. The increase in 2014 was primarily attributable to a milestone payment of approximately $500,000 received under a licensing agreement with ReNeuron Ltd. and a licensing fee of approximately $400,000 in connection with our divestiture of the SC Proven business entered into with Takara Bio Inc., a publicly traded Japanese company."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use